Volume 1.24 | Jul 2

Prostate Cell News 1.24, July 2, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Scientists Develop Highly Specific Antibody to Detect Common Malignant Tissue Changes in Prostate Cancer  
Researchers have developed a highly specific assay for the detection of ERG, a protein associated with tumor formations which is present in more than half of all prostate cancers. [Press release from the Uniformed Services University of the Health Sciences discussing online prepublication in Prostate Cancer and Prostatic Diseases]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies


Statins Associated with Lower Cancer Recurrence Following Prostatectomy
Men who use statins to lower their cholesterol are 30 percent less likely to see their prostate cancer come back after surgery compared to men who do not use the drugs, according to researchers. [Press release from Duke University Medical Center discussing online prepublication in Cancer]

New Research Model of Human Prostate Cancer Shows Cancer Development
Progress toward understanding the role of sex hormones in the growth of prostate cancer has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression. [Press release from EurekAlert! discussing research presented at The Endocrine Society’s 92nd Annual Meeting in San Diego]

PSA Test Does Cut Prostate Cancer Deaths, Study Finds
Adding to the ongoing debate on the usefulness of the prostate-specific antigen blood test for prostate cancer, new research from Sweden finds the screen cuts lives lost to the disease by almost half. [Press release from HealthDay discussing online prepublication in The Lancet Oncology]

Watch Procedure Now  

Culture and Characterize Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Nanoparticle-Induced Vascular Blockade in Human Prostate Cancer
Previous results show that CREKA-coated superparamagnetic iron oxide particles can cause additional clotting in tumor vessels, which creates more binding sites for the peptide. Researchers have used this self-amplifying homing system to develop theranostic nanoparticles that simultaneously serve as an imaging agent and inhibit tumor growth by obstructing tumor circulation through blood clotting. [Blood]

Nrdp1-Mediated Regulation of ErbB3 Expression by the Androgen Receptor in Androgen-Dependent but not Castrate-Resistant Prostate Cancer Cells
Here, researchers show that androgen withdrawal (AW) can promote castration-resistant prostate cancer development by increasing the levels of the receptor tyrosine kinase ErbB3 in androgen-dependent prostate cancer, resulting in AW-resistant cell cycle progression and increased androgen receptor transcriptional activity. [Cancer Res]

STAMP1 Is Both a Proliferative and an Antiapoptotic Factor in Prostate Cancer
Here, researchers find that ectopic expression of STAMP1 significantly increased proliferation of DU145 prostate cancer cells as well as COS-7 cells in vitro; conversely, small interfering RNA-mediated knockdown of STAMP1 expression in LNCaP cells inhibited cell growth and, at least partially, induced cell cycle arrest. [Cancer Res]

Opposing Roles of Dnmt1 in Early and Late Stage Murine Prostate Cancer
Here, researchers utilized Dnmt1 hypomorphic alleles to examine the role of Dnmt1 in normal prostate development, and prostate cancer in TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP). [Mol Cell Biol]

The Functional Significance of MicroRNA-145 in Prostate Cancer
One of the genes significantly upregulated by microRNA-145 overexpression is the proapoptotic gene TNFSF10. Therefore, modulation of microRNA-145 may be an important therapeutic approach for the management of prostate cancer. [Br J Cancer]

VMY-1-103, A Dansylated Analog of Purvalanol B, Induces Caspase-3-Dependent Apoptosis in LNCaP Prostate Cancer Cells
The results demonstrate that VMY-1-103 was more effective in inducing apoptosis in prostate cancer cells than its parent compound, purvalanol B, and support the testing of VMY-1-103 as a potential small molecule inhibitor of prostate cancer in vivo. [Cancer Biol Ther]

ERG Oncoprotein Expression in Prostate Cancer: Clonal Progression of ERG-Positive Tumor Cells and Potential for ERG-Based Stratification
Through exhaustive evaluations of 132 whole-mount prostates for the ERG oncoprotein nuclear expression, researchers demonstrated 99.9% specificity for detecting prostate tumor cells using a highly specific anti-ERG monoclonal antibody. [Prostate Cancer Prostatic Dis]


Baseline PSA as a Predictor of Prostate Cancer-Specific Mortality Over the Past Two Decades
The Duke Prostate Center database was used to identify men who had their PSA level measured over the past 20 years. The Cox proportional hazards model was used to assess whether baseline PSA, race, and age at baseline PSA could predict death from prostate cancer and death from all causes after baseline PSA measurement. [Cancer]


OHSU Knight Cancer Institute Among First in Nation to Treat Prostate Cancer Patients With New Immunotherapy
The Oregon Health & Science University Knight Cancer Institute will be among the first sites in the nation to treat advanced prostate cancer patients with the newest drug approved by the FDA to fight the disease. [OHSU Knight Cancer Institute Press Release]

OncoGenex Pharmaceuticals Announces Initiation of a Phase III Trial in Men with Metastatic Prostate Cancer
OncoGenex Pharmaceuticals, Inc. announced the initiation of a Phase III registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer. [OncoGenex Pharmaceuticals, Inc. Press Release]


NIBIB and the Indian Department of Biotechnology Collaborate to Develop Low-Cost Medical Devices
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) announced the availability of supplemental funding for eligible NIBIB-supported research grants to facilitate collaborative work among researchers in the United States and India. [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings [National Institutes of Health, United States]

Extension of Expiration Date and Additional Receipt Dates for RFA-AI-10-014: Ancillary Studies in Immunomodulation Clinical Trials (R01) (NOT-AI-10-035)  [National Institutes of Health, United States]

Development of Articles for Rare Diseases [Food and Drug Administration, United States]


Translational Cancer Medicine 2010 – USA
July 11-14, 2010
San Francisco, United States

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2)
August 2-4, 2010
Singapore City, Singapore

CHI’s 5th Annual Immunotherapeutics and Vaccine Summit (ImVacS)
August 17-19, 2010
Cambridge, United States

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us